Antiretroviral therapy (ART) is a combination of medicines that stops HIV from making copies of itself inside your body. It doesn’t cure the virus, but it suppresses it so effectively that most people on treatment reach an undetectable viral load within six months, meaning the amount of virus in their blood is too low to measure on standard tests. At that point, HIV can no longer damage the immune system, and it cannot be sexually transmitted to another person.
How ART Blocks the Virus
HIV infects a specific type of immune cell called a CD4 cell. Once inside, it hijacks the cell’s machinery to produce more copies of itself, destroying the cell in the process. Left unchecked, this cycle gradually strips the immune system of the cells it needs to fight infections.
The virus goes through seven distinct stages to replicate: binding to a CD4 cell, fusing with its outer membrane, converting its own genetic material into a form compatible with human DNA, inserting that DNA into the cell’s genome, using the cell to produce viral proteins, assembling new virus particles, and finally budding off the cell surface as a mature, infectious virus. ART works by interrupting this cycle at multiple points simultaneously. A typical regimen combines drugs from at least two different classes, each designed to block a different stage. One drug might prevent the virus from inserting its genetic code into the cell, while another stops it from converting its RNA into DNA in the first place. By attacking multiple stages at once, ART makes it extremely difficult for the virus to complete its life cycle.
The Major Drug Classes
There are seven classes of antiretroviral drugs currently approved, each targeting a specific step in HIV replication:
- Entry inhibitors prevent HIV from latching onto the surface of a CD4 cell, blocking the very first contact.
- Fusion inhibitors stop the virus from merging with the cell membrane, keeping it locked outside.
- NRTIs and NNRTIs (two separate classes) both interfere with an enzyme HIV needs to convert its genetic material into DNA. Without this conversion, the virus can’t proceed.
- Integrase inhibitors block the enzyme that stitches viral DNA into the cell’s own genome. These are among the most commonly prescribed drugs in modern regimens.
- Protease inhibitors prevent newly assembled virus particles from maturing into infectious copies.
- Capsid inhibitors disrupt the protein shell that encases the virus’s genetic material, interfering with proper assembly of new particles.
Most people take a single pill containing two or three drugs from different classes. For those who prefer not to take daily pills, a long-acting injectable option now exists. It consists of two shots given by a healthcare provider either once a month or once every two months, and it’s available for people who have already achieved viral suppression on a daily regimen for at least three to six months.
How the Immune System Recovers
Once ART suppresses viral replication, your CD4 cell count starts climbing. A healthy immune system typically has more than 500 CD4 cells per cubic millimeter of blood. Most people on effective treatment see their counts rise into that normal range over time. The earlier you start treatment after diagnosis, the better the chances of a full recovery. People who begin ART when their immune system is already severely weakened (below 200 cells) can still recover, but the process takes longer and may not reach the same levels.
Doctors consider a CD4 increase of fewer than 200 cells above baseline after two years a sign of suboptimal recovery. This is more common in people who started treatment late, but even with slower recovery, viral suppression itself provides significant protection against infections.
What “Undetectable” Means for Transmission
One of the most significant findings in HIV research is that people with a suppressed viral load do not transmit the virus sexually. The PARTNER study, published in The Lancet, followed couples where one partner had HIV and the other did not. Among thousands of instances of condomless sex while the HIV-positive partner was on suppressive ART, the transmission rate was zero. This held true for both heterosexual and gay couples, forming the basis of the widely cited principle: undetectable equals untransmittable, or U=U.
Reaching undetectable status typically takes up to six months after starting treatment. Maintaining it requires consistent adherence to the medication regimen.
Why Adherence Matters
HIV mutates frequently as it replicates. When drug levels in the body drop because of missed doses, the virus gets a window to multiply. During that window, some copies may develop mutations that make them resistant to the drugs. Once resistance develops, those medicines stop working, and you’ll need to switch to a different regimen.
Even occasional missed doses create this risk. The virus doesn’t need many opportunities to evolve around a drug. This is one reason ART uses multiple drug classes together: even if the virus develops a workaround for one drug, the others are still blocking replication at different stages. But that safety net weakens if adherence slips across the board. Sticking closely to the prescribed schedule is the single most important thing you can do to keep treatment effective long-term.
Life Expectancy on Treatment
People living with HIV who start ART and maintain viral suppression now have a life expectancy within a few years of the general population. A large collaborative study published in The Lancet found that a 40-year-old man who started modern ART could expect to live to about 77, compared to roughly 81 in the general population. For women, the figures were about 79 versus 86. Those who started treatment more recently fared better than those who began older regimens, reflecting improvements in both drug effectiveness and tolerability over time.
The remaining gap is partly explained by higher rates of smoking, diabetes, and other risk factors in the HIV population rather than the virus alone.
Long-Term Health Considerations
While ART has transformed HIV into a manageable condition, long-term treatment comes with some health considerations. People with HIV on ART experience certain age-related conditions at higher rates than the general population, including cardiovascular disease, weight gain, insulin resistance, and changes in cholesterol levels. Three factors drive this: traditional risk factors like smoking and diabetes are more common in this population, some antiretroviral drugs can affect metabolism, and HIV-related inflammation persists at low levels even when the virus is fully suppressed.
These aren’t reasons to avoid treatment. The benefits of ART vastly outweigh these risks. But they do mean that routine health monitoring, including cholesterol checks and cardiovascular risk assessment, becomes an important part of long-term care for people living with HIV.
When to Start Treatment
The World Health Organization recommends starting ART within seven days of an HIV diagnosis, including same-day initiation when possible. Early treatment reduces mortality, achieves viral suppression faster, and gives the immune system the best chance of recovering fully. There is no CD4 threshold to meet before beginning. Regardless of how healthy you feel or how high your CD4 count is at diagnosis, starting treatment immediately produces better outcomes than waiting.